EN DE
Watch DocMorris AG for free: we tell you when fair value or trend changes.
Data-driven stock valuation

DocMorris AG (DOCM) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of DocMorris AG stock CHF 15.17, price CHF 18.60, that is 18.4% below the price, quality 38 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare CH · ISIN CH0042615283

DA DocMorris AG logo Thin data Nov 10, 2026

DocMorris AG

DOCM · SW
Expensive, weak quality

Our calculation puts a fair price 18% below what the stock costs today.

Moderate debt
Fair value CHF 15.17 · Overvalued
Quality 38/100
Weak Growth (revenue 5y −5.3 %/yr in CHF)
Loss-making · -10.7% net margin (TTM)
Negative free cash flow
Trails peers (1/9)
Narrow moat 9/100 · thin data
Thin data
Estimate
Watch DocMorris AG for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

CHF 210.26 CHF 3.98 Fair Value CHF 15.17 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range CHF 3.98 – CHF 210.26 · fair‑value band CHF 11.37 – CHF 18.96 · the CHF 18.60 price screens above the CHF 15.17 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 10, 2026.

Follow DocMorris in your weekly email

Every Wednesday you see whether DocMorris is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

DocMorris AG operates as an online pharmacy, telemedicine, and healthcare company in Switzerland and internationally.

Show moreShow less

The company offers prescription and over-the-counter medicines, and consumer health products, as well as beauty and personal care products, nutritional supplements, painkillers, and first aid products.

The company also provides professional health care services to doctors, pharmacies, insurers, and health institutions. It sells its products to online mail-order pharmacies, and private individuals under the DocMorris, PromoFarma by DocMorris, and TeleClinic brands.

The company was formerly known as Zur Rose Group AG and changed its name to DocMorris AG in May 2023. DocMorris AG was founded in 1993 and is headquartered in Frauenfeld, Switzerland.

Stock analysis

DocMorris AG (DOCM) currently trades at CHF 18.60, while our estimate is CHF 15.17, 18% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: CHF 11.37 (bear) to CHF 18.96 (bull), the price of CHF 18.60 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 38/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

DocMorris AG reported revenue of CHF 1.1B in FY2025 versus CHF 1.7B in FY2021, a compound −10.2%/yr. Reported net income was −CHF 134M in FY2025.

Key figures

Market cap CHF 909M Small · P/S ratio 0.71 · EPS (TTM) CHF −2.46 · Net margin −10.7% · Return on equity −30.1% · Return on assets (EBIT) −8.8% (5-year average) · Operating margin −6.8% · Revenue (TTM) CHF 1.2B.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 9 out of 100 (low confidence).

What moves the price

The share trades at its 52-week high and 367% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 26% fair-value upside, at −18%, DOCM screens richer than that median.

Fair Value

Bear CHF 11.37 Fair Value CHF 15.17 Bull CHF 18.96
Price CHF 18.60 · Downside -18.4%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 38/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 25
How much profit the company makes from its sales and capital
Quality Growth 39
Are margins and returns getting better?
Cashflow 4
Do the profits arrive as real cash?
Financial strength 49
Debt, balance sheet and risk of trouble
Investment 91
Does it invest with discipline instead of growing at any price?
Low Volatility 1
How calm the share price moves, does not count
Price momentum 100
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 100
Distance to the 52-week high, does not count
New shares 50
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 6/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+10.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−5.3%
Start year 2020 (pandemic). Over 10 years: +3.0% a year
Revenue growth 15 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.7%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−8.0% (2020) → −7.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

DOCM screens overvalued: fair value 18% below the price. Compare with JD Health International Inc →

Compare DocMorris AG with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceutical Retailers · 51 stocks

Beats the industry median on 1/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 38 · Bottom 25%
Fair Value upside −18.4% · Bottom 25%
Profitability
Return on assets −16.3% · Bottom 25%
Net margin (12 months) −10.7% · Bottom 25%
Operating margin (12 months) −6.8% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 14.9% · Top 25%
Balance sheet
Debt / equity 0.61× · Highest 25%

Valuation Multiplesvs Pharmaceutical Retailers median · lower = cheaper

P/B 2.22× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (12 months) 0.77× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)9 · sector 65
FUTURE (revenue growth)75 · sector 20
PAST (return on equity)0 · sector 26
HEALTH (low debt)70 · sector 95
DIVIDEND (yield)0 · sector 57

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Pharmaceutical Retailers stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Al-Dawaa Medical Services Company 4163 38.56 SAR 79.49 SAR +106% vs DOCM
JD Health International Inc 6618 HK$42.84 HK$75.61 +76% vs DOCM
Yifeng Pharmacy Chain Co 603939 ¥24.53 ¥40.59 +65% vs DOCM
Yixintang Pharmaceutical Group 002727 ¥12.81 ¥18.92 +48% vs DOCM
DaShenLin Pharmaceutical Group 603233 ¥20.28 ¥25.52 +26% vs DOCM
MedPlus Health Services Limited MEDPLUS ₹596.00 ₹707.67 +19% vs DOCM
LBX Pharmacy Chain Joint Stock Company 603883 ¥14.19 ¥16.43 +16% vs DOCM
Anhui Huaren Health Pharmaceutical Co 301408 ¥14.22 ¥15.40 +8% vs DOCM
ShuYu Civilian Pharmacy Corp 301017 ¥14.64 ¥5.91 −60% vs DOCM
Apotea AB APOTEA kr 105.60 kr 39.50 −63% vs DOCM

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

DocMorris AG: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "DocMorris AG Fair Value". https://www.fairvalue-calculator.com/stock/DOCM

Frequently asked questions

Is DocMorris AG (DOCM) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is CHF 15.17 versus a price of CHF 18.60, about 18% lower (overvalued).
What is the fair value of DOCM?
Our estimate for DocMorris AG is CHF 15.17 (as of Nov 10, 2026), built from audited fundamentals. The current price: CHF 18.60.
What is the quality score of DOCM?
DocMorris AG has a Quality Score of 38/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for DocMorris AG (DOCM)?
Our calculated price target is the estimate of CHF 15.17 (as of Nov 10, 2026). Cautious scenario CHF 11.37, optimistic scenario CHF 18.96. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the DocMorris AG stock forecast for 2026?
Our estimate puts fair value at CHF 15.17, about 18% lower versus a price of CHF 18.60 (overvalued). Cautious scenario CHF 11.37, optimistic scenario CHF 18.96. The calculation is refreshed regularly with new filings.
What is the revenue of DocMorris AG (DOCM)?
DocMorris AG reported trailing-twelve-month revenue of about CHF 1.2B (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of DocMorris AG (DOCM)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For DocMorris AG it is CHF 15.17 per share (as of Nov 10, 2026), against a price of CHF 18.60.
Is DocMorris AG stock overvalued or undervalued in 2026?
As of Nov 10, 2026, DOCM trades above its calculated fair value: price CHF 18.60, fair value CHF 15.17, a gap of about −18% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of DOCM?
No. The price is what the market pays today (CHF 18.60); the fair value is what the company's own numbers justify (CHF 15.17). For DocMorris AG the two are CHF 3.43 per share apart. That gap is exactly why we show both numbers side by side.
How much is DocMorris AG worth?
The market values DocMorris AG at about CHF 909M (market capitalisation, as of Nov 10, 2026). Per share that is CHF 18.60; our models calculate a fair value of CHF 15.17 per share.
What do the bullish and bearish scenarios say about DOCM?
Our models span a range for DocMorris AG: cautious scenario CHF 11.37, base CHF 15.17, optimistic CHF 18.96 per share (as of Nov 10, 2026, price CHF 18.60). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of DocMorris AG (DOCM)?
Balance-sheet figures for DocMorris AG (as of Nov 10, 2026): return on equity −30.1%, debt of 0.61 per unit of equity. They feed the Quality Score of 38/100, which measures business quality independently of the share price.
How far is DOCM from its 52-week high?
DocMorris AG trades at CHF 18.60, at its 52-week high of CHF 18.60 and 367% above the low of CHF 3.98 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of CHF 15.17 is for.
Which stocks are comparable to DocMorris AG?
From the same area (Healthcare) we also value JD Health International Inc, Yifeng Pharmacy Chain Co, DaShenLin Pharmaceutical Group, LBX Pharmacy Chain Joint Stock Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is DocMorris AG stock attractive at the current price?
The data as of Nov 10, 2026: price CHF 18.60, calculated fair value CHF 15.17 (−18%), Quality Score 38/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.7% above its aggregate fair value. DocMorris AG itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of DocMorris AG (DOCM)?
The closing price on Nov 10, 2026 was CHF 18.60. Our estimate is CHF 15.17, about 18% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with DocMorris AG right now?
Weak quality (38/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of DocMorris AG

How large is the market capitalisation of DocMorris AG (DOCM)?
The market capitalisation of DocMorris AG is CHF 909M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of DocMorris AG (DOCM)?
The price-to-sales ratio of DocMorris AG is 0.71 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of DocMorris AG (DOCM)?
Earnings per share at DocMorris AG are CHF −2.46. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of DocMorris AG (DOCM)?
The net margin of DocMorris AG is −10.7% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of DocMorris AG (DOCM)?
The return on equity (ROE) of DocMorris AG is −30.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of DocMorris AG (DOCM)?
On an EBIT basis the return on assets of DocMorris AG is −8.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of DocMorris AG (DOCM)?
The operating margin of DocMorris AG is −6.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at DocMorris AG (DOCM)?
Revenue at DocMorris AG is growing +14.9% versus a year earlier (3y avg +6.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does DocMorris AG (DOCM) generate?
The free cash flow of DocMorris AG is −CHF 90.0M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does DocMorris AG (DOCM) carry?
The net debt of DocMorris AG is CHF 169M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch DocMorris AG in the live analysis

One click puts DocMorris AG on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.